Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Sage Therapeutics Inc

Healthcare US SAGE

NoneUSD
0.00(0%)

Last update at 2025-09-04T20:10:53.594363Z

Day Range

--
LowHigh

52 Week Range

10.9259.99
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap708.94M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-507.26202M
  • Revenue TTM91.06M
  • Revenue Per Share TTM1.52
  • Gross Profit TTM -319.29000M
  • Diluted EPS TTM-8.39

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -532.78400M -457.89200M 606.07M -680.23800M -372.88200M
Minority interest - - - - -
Net income -503.26700M -450.82700M 606.07M -650.15100M -372.88200M
Selling general administrative 227.70M 183.50M 196.95M 345.78M 201.40M
Selling and marketing expenses - - - - 44.60M
Gross profit 6.87M 5.75M 1113.63M 6.47M 90.27M
Reconciled depreciation 1.12M 4.18M 2.63M 2.28M 1.14M
Ebit -548.11100M -465.09100M 596.23M -710.40700M -394.38100M
Ebitda -546.98900M -460.90900M 651.71M -708.12400M -393.23800M
Depreciation and amortization 1.12M 4.18M 55.49M 2.28M 1.14M
Non operating income net other 0.01M 0.13M 0.25M 0.08M 0.02M
Operating income -546.98900M -460.90900M 596.23M -708.12400M -393.23800M
Other operating expenses 554.67M 467.22M 490.23M 714.99M 483.51M
Interest expense 14.19M 7.20M 0.00000M 0.00000M 0.00000M
Tax provision - - - - -
Interest income 14.19M 2.88M 9.60M 27.80M 20.33M
Net interest income 14.19M 2.88M 9.60M 27.80M 20.33M
Extraordinary items - - - - -
Non recurring - - 27.74M - -
Other items - - - - -
Income tax expense -29.51700M -7.06500M 15.52M -30.08700M 20.36M
Total revenue 7.69M 6.31M 1114.20M 6.87M 90.27M
Total operating expenses 553.86M 466.66M 489.67M 714.59M 483.51M
Cost of revenue 0.81M 0.55M 0.56M 0.40M 282.11M
Total other income expense net 14.21M 3.02M 9.85M 27.89M 0.02M
Discontinued operations - - - - -
Net income from continuing ops -532.78400M -457.89200M 606.07M -680.23800M -372.88200M
Net income applicable to common shares -532.78400M -457.89200M 606.07M -680.23800M -372.88200M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 882.28M 1356.45M 1825.29M 2159.25M 1084.15M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 31.82M 50.83M 58.35M 22.82M 26.70M
Total liab 82.75M 103.85M 96.26M 86.91M 139.50M
Total stockholder equity 799.53M 1252.60M 1729.03M 2072.33M 944.65M
Deferred long term liab - - - - -
Other current liab 67.26M 72.67M 67.28M 54.85M 86.62M
Common stock 0.00600M 0.00600M 0.00600M 0.00600M 0.00500M
Capital stock 0.00600M 0.00600M 0.00600M 0.00600M 0.00500M
Retained earnings -2569.65900M -2028.17000M -1495.38600M -1037.49400M -1643.56700M
Other liab - 0.10M 0.10M 0.27M 0.52M
Good will - - - - -
Other assets - 6.04M 5.52M 5.06M 6.16M
Cash 70.99M 162.70M 294.23M 1661.08M 126.70M
Cash and equivalents - - - - -
Total current liabilities 82.75M 99.26M 85.19M 67.20M 112.13M
Current deferred revenue - - - - -
Net debt -65.82700M -150.56600M -275.80100M -1632.98200M -89.61300M
Short term debt 5.17M 7.64M 7.47M 8.66M 10.24M
Short long term debt - - - - -
Short long term debt total 5.17M 12.13M 18.43M 28.10M 37.09M
Other stockholder equity 3370.00M 3290.97M 3227.07M 3109.41M 2586.92M
Property plant equipment - 2.90M 19.12M 6.75M 9.13M
Total current assets 869.35M 1272.49M 1800.64M 2122.37M 1035.09M
Long term investments - - - - -
Net tangible assets - 1252.60M 1729.03M 2072.33M 944.65M
Short term investments 682.19M 1109.79M 1448.06M 438.47M 881.69M
Net receivables 83.01M 13.66M 18.51M - -
Long term debt - - - - -
Inventory 1.33M -64.48600M -18.50600M - -
Accounts payable 10.32M 18.95M 10.45M 3.69M 15.27M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.81400M -10.20600M -2.66000M 0.41M 1.29M
Additional paid in capital - - - - -
Common stock total equity - 0.00600M 0.00600M 0.00600M 0.00500M
Preferred stock total equity - - - - -
Retained earnings total equity - -2028.17000M -1495.38600M -1037.49400M -1643.56700M
Treasury stock - - - - -0.40000M
Accumulated amortization - - - - -
Non currrent assets other 6.55M 70.53M 5.52M 5.06M 6.16M
Deferred long term asset charges - - - - -
Non current assets total 12.93M 83.95M 24.64M 36.88M 49.06M
Capital lease obligations 5.17M 12.13M 18.43M 28.10M 37.09M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 326.37M -1002.07600M 443.03M -137.40500M -509.60100M
Change to liabilities 13.05M 6.69M -43.66800M 15.02M 34.67M
Total cashflows from investing activities 325.43M -1002.44800M 442.68M -143.15600M -512.46100M
Net borrowings - - - -0.32800M -0.34000M
Total cash from financing activities 3.07M 13.33M 426.76M 607.62M 659.36M
Change to operating activities -2.76200M -25.19500M -28.21800M 25.44M -5.33200M
Net income -532.78400M -457.89200M 606.07M -680.23800M -372.88200M
Change in cash -131.53300M -1367.29600M 1533.73M -64.23800M -113.77400M
Begin period cash flow 295.50M 1662.80M 129.07M 193.31M 307.08M
End period cash flow 163.97M 295.50M 1662.80M 129.07M 193.31M
Total cash from operating activities -460.03600M -378.18200M 664.28M -528.70600M -260.67100M
Issuance of capital stock 0.00000M 0.00000M 417.50M 561.28M 631.49M
Depreciation 1.12M 4.18M 2.63M 2.28M 1.14M
Other cashflows from investing activities - - - -137.40500M -509.60100M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock 3.11M 14.72M 9.26M 610.13M 660.60M
Other cashflows from financing activities 3.07M 13.33M 9.26M 46.35M 27.86M
Change to netincome 60.10M 94.03M 94.26M 149.56M 101.75M
Capital expenditures 0.94M 0.37M 0.34M 5.75M 2.86M
Change receivables 4.85M -18.50600M - - -
Cash flows other operating -12.22500M -18.44700M 3.94M -8.36300M -15.46200M
Exchange rate changes - - - - -
Cash and cash equivalents changes -131.53300M -1367.29600M 1533.73M -64.23800M -113.77400M
Change in working capital 5.67M -18.50600M -39.72900M 6.66M 19.21M
Stock based compensation 61.60M 104.63M 95.99M 153.23M 101.96M
Other non cash items 4.35M -10.59500M -0.68800M -10.64000M -10.10700M
Free cash flow -460.97300M -378.55400M 663.93M -534.45700M -263.53100M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SAGE
Sage Therapeutics Inc		 - -% - - - 10.73 1.16 2.10 -0.3325
NVO
Novo Nordisk A/S		 0.04 0.09% 43.92 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 0.40 0.91% 44.40 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.54 1.24% 450.46 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 2.84 0.46% 614.98 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Sage Therapeutics Inc

215 First Street, Cambridge, MA, United States, 02142

Key Executives

Name Title Year Born
Mr. Barry E. Greene Pres, CEO & Director 1963
Ms. Kimi E. Iguchi CPA CFO & Treasurer 1962
Dr. Albert J. Robichaud Ph.D. Chief Scientific Officer 1961
Mr. Christopher Benecchi Chief Bus. Officer 1972
Mr. Matt Lasmanis Chief Technology & Innovation Officer NA
Helen Rubinstein Investor Relations Officer NA
Ms. Anne Marie Cook Esq. Sr. VP, Gen. Counsel & Sec. 1962
Ms. Erin E. Lanciani Chief People & Experience Officer 1969
Dr. Amy Schacterle Ph.D. Sr. VP of R&D Strategy and Bus. Management NA
Dr. Jim Doherty Ph.D. Chief Devel. Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.